Document is current
Any future updates will be listed below
-
Authors
Islam, Tohidul https://orcid.org/0000-0003-1561-944X
Hill, Emily
Abrahamson, Eric E.
Servaes, Stijn
Smirnov, Denis S.
Zeng, Xuemei
Sehrawat, Anuradha
Chen, Yijun https://orcid.org/0009-0001-4579-4057
Kac, Przemysław R. https://orcid.org/0000-0001-5083-0924
Kvartsberg, Hlin https://orcid.org/0000-0002-4481-508X
Olsson, Maria
Sjons, Emma https://orcid.org/0009-0008-5030-114X
Gonzalez-Ortiz, Fernando https://orcid.org/0000-0001-7897-9456
Therriault, Joseph
Tissot, Cécile https://orcid.org/0000-0003-2711-3833
Del Popolo, Ivana https://orcid.org/0009-0005-6480-4117
Rahmouni, Nesrine
Richardson, Abbie
Mitchell, Victoria
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Pascoal, Tharick A. https://orcid.org/0000-0001-9057-8014
Lashley, Tammaryn https://orcid.org/0000-0001-7389-0348
Wall, Mark J.
Galasko, Douglas
Rosa-Neto, Pedro https://orcid.org/0000-0001-9116-1376
Ikonomovic, Milos D.
Blennow, Kaj https://orcid.org/0000-0002-1890-4193
Karikari, Thomas K. https://orcid.org/0000-0003-1422-4358
- License Information
-
More Information
Article History
Received: 28 March 2024
Accepted: 2 November 2024
First Online: 10 February 2025
Competing interests
: T.K.K., E.E.A. and M.D.I. are inventors on a US patent filed by the University of Pittsburgh based on the IHC and fluorescence labeling findings included in this work (63/679,361: Methods to Evaluate Early-Stage Pre-Tangle TAU Aggregates and Treatment of Alzheimer’s Disease Patients), while T.K.K. is the inventor on an additional University of Pittsburgh patent application (63/693,956: Anti-tau Protein Antigen Binding Reagents) on anti-tau antibodies, including those targeting the STA core region and selected phosphorylation sites within this region. T.K.K. has served as a consultant for the Quanterix Corporation, outside the submitted work. H.Z. has served on scientific advisory boards or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave. He has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk and Roche, and is a cofounder of Brain Biomarker Solutions (BBS), which is a part of the GU Ventures Incubator Program (outside the submitted work). D.G. has consulted for Eisai, GE Healthcare and Artery Therapeutics. K.B. has served as a consultant and on advisory boards for Abbvie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly and Moleac, Neurimmune, Novartis, Ono Pharma, Prothena, Roche Diagnostics and Siemens Healthineers. He has served on data monitoring committees for Julius Clinical and Novartis; he has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and he is a cofounder of BBS, which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. M.D.I. has received research funding from Avid Radiopharmaceuticals. The other authors declare no competing interests.
